Unknown

Dataset Information

0

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.


ABSTRACT: In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer patients. Although antibody therapy has continuously been improved, still a significant number of patients do not benefit from antibody therapy. Therefore, rational optimization of the antibody molecule by Fc engineering represents a major area of translational research to further improve this potent therapeutic option. Monoclonal antibodies are able to trigger a variety of effector mechanisms. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement- dependent cytotoxicity (CDC) are considered important in antibody therapy of cancer. Novel mechanistic insights into the action of monoclonal antibodies allowed the development of various Fc engineering approaches to modulate antibodies' effector functions. Strategies in modifying the Fc glycosylation profile (Fc glyco-engineering) or approaches in engineering the protein backbone (Fc protein engineering) have been intensively evaluated. In the current review, Fc engineering strategies resulting in improved ADCC, ADCP and CDC activity are summarized and discussed.

SUBMITTER: Kellner C 

PROVIDER: S-EPMC5649276 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Kellner Christian C   Otte Anna A   Cappuzzello Elisa E   Klausz Katja K   Peipp Matthias M  

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 20170908 5


In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer patients. Although antibody therapy has continuously been improved, still a significant number of patients do not benefit from antibody therapy. Therefore, rational optimization of the antibody molecule by Fc engineering represents a major area of translational research to further improve this potent therapeutic option. Monoclonal antibodies are able to trigger a variety of effector mechanisms. Especially Fc  ...[more]

Similar Datasets

| S-EPMC5777978 | biostudies-literature
| S-EPMC4432726 | biostudies-literature
| S-EPMC5149539 | biostudies-literature
| S-EPMC9916680 | biostudies-literature
| S-EPMC10168116 | biostudies-literature
| S-EPMC3216605 | biostudies-literature
| S-EPMC8691596 | biostudies-literature
| S-EPMC6698841 | biostudies-literature
| S-EPMC10585040 | biostudies-literature
| S-EPMC8139315 | biostudies-literature